220 related articles for article (PubMed ID: 9708403)
1. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients.
Casado JL; Perez-Elías MJ; Antela A; Sabido R; Martí-Belda P; Dronda F; Blazquez J; Quereda C
AIDS; 1998 Jul; 12(11):F131-5. PubMed ID: 9708403
[TBL] [Abstract][Full Text] [Related]
2. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients.
Fätkenheuer G; Theisen A; Rockstroh J; Grabow T; Wicke C; Becker K; Wieland U; Pfister H; Reiser M; Hegener P; Franzen C; Schwenk A; Salzberger B
AIDS; 1997 Nov; 11(14):F113-6. PubMed ID: 9386799
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor.
Grabar S; Pradier C; Le Corfec E; Lancar R; Allavena C; Bentata M; Berlureau P; Dupont C; Fabbro-Peray P; Poizot-Martin I; Costagliola D
AIDS; 2000 Jan; 14(2):141-9. PubMed ID: 10708284
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir.
Kirk O; Mocroft A; Pradier C; Bruun JN; Hemmer R; Clotet B; Miller V; Viard JP; Phillips AN; Lundgren JD;
AIDS; 2001 May; 15(8):999-1008. PubMed ID: 11399982
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection.
d'Arminio Monforte A; Testa L; Adorni F; Chiesa E; Bini T; Moscatelli GC; Abeli C; Rusconi S; Sollima S; Balotta C; Musicco M; Galli M; Moroni M
AIDS; 1998 Sep; 12(13):1631-7. PubMed ID: 9764782
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens.
Hall CS; Raines CP; Barnett SH; Moore RD; Gallant JE
AIDS; 1999 Jul; 13(10):1207-12. PubMed ID: 10416524
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed.
Zolopa AR; Shafer RW; Warford A; Montoya JG; Hsu P; Katzenstein D; Merigan TC; Efron B
Ann Intern Med; 1999 Dec; 131(11):813-21. PubMed ID: 10610625
[TBL] [Abstract][Full Text] [Related]
9. Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.
Chêne G; Binquet C; Moreau JF; Neau D; Pellegrin I; Malvy D; Ceccaldi J; Lacoste D; Dabis F
AIDS; 1998 Dec; 12(17):2313-20. PubMed ID: 9863874
[TBL] [Abstract][Full Text] [Related]
10. The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study.
Rhone SA; Hogg RS; Yip B; Sherlock C; Conway B; Schechter MT; O'Shaughnessy MV; Montaner JS
AIDS; 1998 Apr; 12(6):619-24. PubMed ID: 9583602
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of protease inhibitor based antiretroviral combination therapy--a prospective cohort study.
Salzberger B; Rockstroh J; Wieland U; Franzen C; Schwenk A; Jütte A; Hegener P; Cornely O; Mörchen C; Gaensicke T; Diehl V; Fätkenheuer G
Eur J Med Res; 1999 Nov; 4(11):449-55. PubMed ID: 10585299
[TBL] [Abstract][Full Text] [Related]
13. Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals.
Kaufmann GR; Duncombe C; Cunningham P; Beveridge A; Carr A; Sayer D; French M; Cooper DA
AIDS; 1998 Sep; 12(13):1625-30. PubMed ID: 9764781
[TBL] [Abstract][Full Text] [Related]
14. Patients failing saquinavir therapy require an early change to indinavir before HIV-1 viral load reaches high levels.
Dronda F; Pérez-Elías MJ; Antela A; Casado JL; Martí-Belda P; Cobo J
Antivir Ther; 1999; 4(2):117-21. PubMed ID: 10682157
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial.
Kirk O; Katzenstein TL; Gerstoft J; Mathiesen L; Nielsen H; Pedersen C; Lundgren JD
AIDS; 1999 Jan; 13(1):F9-16. PubMed ID: 10207539
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).
Cohen Stuart JW; Schuurman R; Burger DM; Koopmans PP; Sprenger HG; Juttmann JR; Richter C; Meenhorst PL; Hoetelmans RM; Kroon FP; Bravenboer B; Hamann D; Boucher CA; Borleffs JC
AIDS; 1999 May; 13(7):F53-8. PubMed ID: 10357371
[TBL] [Abstract][Full Text] [Related]
17. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
[TBL] [Abstract][Full Text] [Related]
18. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
Schapiro JM; Winters MA; Lawrence J; Merigan TC
AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
[TBL] [Abstract][Full Text] [Related]
19. [Long-term immunologic response in HIV-infected patients with CD4 cell counts = 50/mm3 when initiating protease inhibitor therapy].
Le Moing V; Eid Z; Ecobichon JL; Duval X; Longuet P; Elbim C; Brun-Vezinet F; Leport C; Vilde JL
Ann Med Interne (Paris); 2001 Feb; 152(1):11-4. PubMed ID: 11240420
[TBL] [Abstract][Full Text] [Related]
20. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease.
Piketty C; Castiel P; Belec L; Batisse D; Si Mohamed A; Gilquin J; Gonzalez-Canali G; Jayle D; Karmochkine M; Weiss L; Aboulker JP; Kazatchkine MD
AIDS; 1998 May; 12(7):745-50. PubMed ID: 9619806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]